Goodwin > London, England > Firm Profile

Goodwin
100 CHEAPSIDE
LONDON
EC2V 6DY
England

Investment fund formation and management > Real estate funds Tier 1

Goodwin‘s real estate funds team is co-led by ‘exceptional partner’ Justin Cornelius and the ‘simply outstanding’ Samantha Lake Coghlan, and is known for its expertise in real estate funds topics affecting the market and industry.  The team regularly collaborates with its Luxembourg office on cross-border matters, with its recent work also seeing significant demand from a diverse set of investors from Europe, the Americas, Asia and the Middle East. The broad range of asset classes the funds team covers includes office, retail, residential, multifamily, industrial, hospitality, senior housing and assisted living, student housing, logistics and infrastructure, it also represents a broad range of investor types, being public pensions, sovereign wealth funds, insurance companies, foundations, family offices and private banks. Partner David Evans has particular expertise dealing with complex tax and real estate issues for both UK and pan-European funds.

Practice head(s):

Samantha Lake Coghlan; Justin Cornelius

Other key lawyers:

David Evans; Greg Barclay; Adnan Bhaiji; Bhargavi Mudakavi

Testimonials

‘Justin Cornelius and his support team are all very talented.’

‘Justin Cornelius is an exceptional partner who always finds time for us and is very pragmatic and solutions-focused.’

‘Market presence, expert knowledge and a pragmatic approach’

‘David Evans, Greg Barclay and Adnan Bhaiji are noteworthy.’

‘Very good, broad industry knowledge and skills as well as an extremely high-level of engagement and client service. We feel like a truly valued client and as though they are an extension of our team.’

‘Samantha Lake Coghlan and Justin Cornelius are simply outstanding; my favourite partners to work with throughout my career. They are supported by strong associates like Bhargavi Mudakavi. The key is their client-centred approach and pragmatic advice.’

Key clients

NREP

Patron

Frogmore

Kennedy Wilson

Slate Asset Management

USAA Real Estate

Ares Management

BentallGreenOak

Nuveen

Clearbell Capital

Work highlights

  • Advised Ares Management on the final closing of Ares European Property Enhancement Partners III; the fund was oversubscribed with approximately €1.5b of commitments compared to its €1b target and is more than twice the size of its 2016 predecessor fund.
  • Advising on the formation and fundraising of Frogmore Real Estate Partners IV, L.P. their fourth value-add and opportunistic fund, targeting investments in the UK.

Corporate and commercial > Corporate and commercial: Cambridge Tier 1

Goodwin's Cambridge office plays a key role in the firm's globally recognised technology and life sciences practice, which frequently assists private and public companies, venture capital funds and investment firms with early-stage financings, capital markets issuance, M&A, strategic collaborations and licensing transactions. David Mardle, Malcolm Bates and Tim Worden are the lead partners. Mardle acted for fast-growing start-up Hopin in its $450m funding round and in the acquisitions of Streamable, Jamm, Boomset and Attendify. Worden assisted spin-out life sciences company In4Derm Limited with a licence agreement for a new oncology treatment. Newly promoted partner Elizabeth Rhodes and associate Adam Thatcher, who both focus on VC and M&A transactions, are also recommended.

Practice head(s):

Malcolm Bates; David Mardle; Tim Worden

Other key lawyers:

Key clients

Moderna

Evox Therapeutics

Kymab

Oxford Biomedica

Calliditas Therapeutics

InBrain

Avacta

SparingVision

CIC

Tropic Biosciences

Index Ventures

MiNA Therapeutics

Avacta Group

Work highlights

  • Advised Teva Pharmaceutical Industries Ltd. on a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433.
  • Advised Calliditas Therapeutics AB on a strategic licence agreement with STADA Arzneimittel AG to register and commercialize a novel specialty drug candidate for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy (IgAN) in the European Economic Area member states, Switzerland and the UK.
  • Advising Kymab on its agreement under which Sanofi will acquire Kymab for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones.

TMT (technology, media and telecoms) > Biotechnology Tier 1

Goodwin has 'an understanding of the biotech landscape, the pressures on biotech companies and the experience in biotech licensing deals globally'. Clients remark that one of its key strengths is its 'experienced associates who work autonomously, closely in communication with partners', resulting in a practice that is 'very responsive and able to provide creative proposals to address potential problems'. Among its clients are pharmaceutical company Teva and gene and cell therapy company Oxford Biomedica. The practice is led by life sciences and technology M&A and finance partner David Mardle, commercial IP specialist Malcolm Bates and licensing and contracts expert Tim Worden, who all work in both the Cambridge and London offices. Newly promoted counsel Talitha Shkopiak specializes in commercial agreements forthe creation and commercialisation of IP rights, notably for biotechnology companies.

Practice head(s):

Malcolm Bates; David Mardle; Tim Worden

Other key lawyers:

Testimonials

‘Understanding of the biotech landscape, the pressures on biotech companies and experience on biotech licensing deals globally.’

‘Experienced associates that work autonomously, closely in communication with partners.’

‘Very responsive and able to provide creative proposals to address potential problems.’

‘Thorough and significant sector knowledge and experience.’

‘I had the opportunity to interact with two different lawyers at Goodwin and I have to say that the negotiation certainly improved thanks to the feedback received and the team style. I was provided with clear recommendations and/or clear consequences from accepting or not the recommendations in a way that the negotiation with the partner became much more intuitive and clear.’

‘They have gravitas and courage to actually help guiding the negotiation when needed.’

‘Extremely positive experience working with the Goodwin team on a pharma licensing transaction. Felt they really cared about the transaction and made themselves available day and night to meet very tight deal deadlines.’

‘Tim Worden is extremely knowledgeable and experienced on all aspects licensing transactions. A very calm but engaging personality. He is very good at highlighting and then resolving different challenges arising in a negotiation. I always have the impression nothing gets past Tim which gives me comfort we have the right lawyer representing us.’

Key clients

Novasep

Oxford Biomedica

Calliditas Therapeutics

CMR Surgical

In4Derm

Orexia Therapeutics

Teva

InBrain

Avacta

SparingVision

SynAffix

Ellipses Pharma

Work highlights

  • Advised Teva Pharmaceutical Industries Ltd on a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433.
  • Advised Calliditas Therapeutics AB on a strategic licence agreement with STADA Arzneimittel AG to register and commercialize a novel specialty drug candidate for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy (IgAN) in the European Economic Area member states, Switzerland and the UK.
  • Advising Kymab on its agreement under which Sanofi will acquire Kymab for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones.

TMT (technology, media and telecoms) > Intellectual property Tier 1

Goodwin‘s Cambridge office has ‘unique experience in life sciences and excellent knowledge of and extensive experience in IP contracting enables the team to provide relevant advice in relation to complex IP arrangements‘. The firm is frequently involved in helping companies to develop emerging life sciences and technologies, including Covid-19 vaccines, and it counts Oxford Biomedica, Teva and Avacta among its high-profile clients. Malcolm Bates (who has ‘a commercial and pragmatic approach to contract negotiations‘) and Tim Worden (who ‘cuts through the underbrush and pushes transactions forward‘) work from both Cambridge and London and lead the technology and life sciences practice. Counsel Talitha Shkopiak and associates Georgia Powell and Samantha Deacon also play pivotal roles in the practice. Worden and Powell assisted University of Dundee spinout In4Derm to licence a new treatment for immunology and oncology conditions.

Practice head(s):

Malcolm Bates; Tim Worden

Testimonials

‘The firm has knowledge of IP practices and IP licensing in biotech, understanding of what is important to biotech companies.’

‘Partners and associates have broad experience on global license agreements and have suggested useful solutions during the negotiation and contract drafting phase.’

‘Malcolm Bates and Tim Worden are excellent, pro-active, business-minded professionals who cut through the underbrush and push transactions forward.’

‘Unique experience in life sciences. Excellent knowledge and extensive experience of IP contracting enables the team to provide relevant advice in relation to complex IP arrangements.’

‘Malcolm Bates is hugely experienced and understands our business and requirements really well. He has a commercial and pragmatic approach to contract negotiations.’

‘Talitha Shkopiak is very tenacious and able to redraft the incomprehensible so that it makes sense!’

‘Georgia Powell has provided reliable, solid advice on a number of agreements.’

Key clients

Novasep

Oxford Biomedica

Calliditas Therapeutics

CMR Surgical

In4Derm

Orexia Therapeutics

Teva

InBrain

Avacta

SparingVision

SynAffix

Ellipses Pharma

Work highlights

  • Advised Teva Pharmaceutical Industries Ltd. on a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433.
  • Advised Calliditas Therapeutics AB on a strategic licence agreement with STADA Arzneimittel AG to register and commercialize a novel specialty drug candidate for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy (IgAN) in the European Economic Area member states, Switzerland and the UK.
  • Advising Kymab on its agreement under which Sanofi will acquire Kymab for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones.

Corporate and commercial > M&A: lower mid-market deals, £50m-£500m Tier 2

Noted for its transatlantic capabilities and technical knowledge, Goodwin is widely lauded for its capabilities advising on big-ticket, cross-border transactions across the tech, life sciences, and real estate sectors. The London office is jointly headed up by several partners: European chair David Evans, a specialist in REIT M&A; James Spence, whose real estate capabilities are concentrated in European investment transactions; UK life sciences co-chair Graham Defries, a regular advisor to a host of biotech and pharmaceutical entities; and David Mardle, a key contact for the firm’s emerging tech company clientele. Recent highlights for the ‘outstandingAndrew Harrow include high-value transatlantic disposals, while Ali Ramadan is reputed for his fintech, proptech, and digital media focus. Eric Lim, an experienced advisor in cross-border real estate transactions, joined the team from Baker McKenzie in March 2022.

Practice head(s):

David Evans; Graham Defries; David Mardle; James Spence

Other key lawyers:

Andrew Harrow; Ali Ramadan; Eric Lim; Richard Bloomfield

Testimonials

‘We worked with Goodwin on the acquisition of our startup. David Mardle was a pleasure to work with – expert and knowledgeable as well as efficient. We felt in safe hands and his calm confidence made the deal much less stressful than it might have been.’

‘The collaboration, the US and English law knowledge, and technical knowledge in tech and software were excellent in all respects.’

‘We were so impressed with Goodwin’s team that we have already highly recommended them for future support and advice whenever required to our new owners. Their capability and excellence, as well as their competitive fees, mean that we will indeed return to them when and if needed for future acquisition deals and related issues.’

‘Excellent collaborators. Very fast, supportive, accurate, and diligent throughout.’

‘The management team were going through this process for the first time at this scale, and the team were quite frankly outstanding in supporting them through such a complex process. Not only did they do what needed to be done, but raised the right questions at the right times and made sure management considered every aspect.’

‘Andrew Harrow and his team were simply outstanding. Very personable, down to earth, and level headed even during the difficult parts of the process.’

Key clients

Centessa Pharmaceuticals Limited

Kymab

Level Equity Growth Partners

Skew Ltd

Weezy Group Ltd

Springer Nature

Captify Technologies Ltd

Dotmatics Ltd

Vaccitech plc

Cabot Properties

Clarion Partners Europe

Glennmont Medical Properties Trust

YASA Limited

Arctos Medical AG

Kennedy Wilson

Biocon Biologics

Syndesi Therapeutics

Minesoft

Work highlights

  • Advised Cabot Properties in its agreement with Blackstone and two vehicles affiliated with Blackstone Real Estate to sell its institutional-quality logistics assets for $2.8bn.
  • Advised Biocon Biologics Ltd. in its definitive agreement to acquire Viatris Inc.’s global biosimilars business for up to $3.335bn.
  • Advised the sellers of YASA Limited on its sale to Daimler UK Limited, part of the Mercedes-Benz group of companies.

Corporate and commercial > Private equity: transactions - mid-market deals (up to £250m) Tier 2

Goodwin‘s work in the private equity space includes acting for a broad and growing client base of mid-market funds on acquisitions, exits and portfolio company M&A. The practice is sector-agnostic, with experience handling deals involving technology, financial services, consumer goods and life sciences companies. In addition to its work in mainstream PE, the practice also handles infrastructure and growth capital deals. Practice head Richard Lever is ‘focused on finding ways to help get the transaction over the line’, with Carl Bradshaw, Gemma Roberts and James Grimwood all highly active in the mid-market PE space. The private equity partners work closely with the firm’s tax and finance partners to provide a comprehensive service to clients.

Practice head(s):

Richard Lever

Other key lawyers:

James Grimwood; Gemma Roberts; Carl Bradshaw; Michael Miranda; John van der North; Michelle Tong

Testimonials

‘Richard Lever is responsive, knowledgable, very much focused on finding ways to help get the transaction over the line.’

 

Key clients

Accel-KKR

Antin Infrastructure Partners

Bregal Milestone

Graphite Capital

Inflexion Private Equity

Levine Leichtman Capital Partners

Mayfair Equity Partners

Queens Park Equity

TA Associates

TowerBrook Capital Partners

Work highlights

  • Advised Levine Leichtman Capital Partners on its acquisition of the entire issued share capital of Prime Global Medical Communications Ltd., a collection of communications solutions agencies focusing on global medical affairs and scientific publications.
  • Acted for Mayfair Equity Partners on a number of matters, including on its acquisition of Tangle Teezer and on a number of portfolio company transactions.
  • Advised Bregal Milestone on the buyout of Redstor.

Corporate and commercial > Venture capital Tier 2

Goodwin‘s strategy several years ago of hiring some of the best names in the industry from numerous leading law firms is continuing to pay off. This, coupled with the firm’s strong corporate finance/funds heritage and US platform, has ensured that in spite of its relative nascence it is already a major presence in the market. Led by David Mardle out of London, but also drawing upon a strong presence in Cambridge, the team has ‘an impressive breadth of expertise and experience’ and is able to ‘handle the most complex transactions with calm authority’. Benefitting from a ‘very commercial mindset’, tech sector expert Ali Ramadan exemplifies the firm’s versatility in the sector, being equally at home handling early stage work for start-ups, as he is in a later stage scenario for investors. As well as conventional technology and life sciences venture mandates, Sophie McGrath also has a core focus on impact investing and ‘is simply stellar when it comes to healthtech deals’. Other recommended practitioners include ‘technical, commercial, cool headed and strategic’ Cambridge-based partner Elizabeth Rhodes; the ‘phenomenal’ Andrew Davis, whose workload includes a considerable amount of transactions in the proptech space; and associate Adam Thatcher, who divides his time between the firm’s Cambridge and London offices.

Practice head(s):

David Mardle

Other key lawyers:

Sophie McGrath; Ali Ramadan; Andrew Davis; Elizabeth Rhodes; Adam Thatcher; Kenny Walker-Durrant; Richard Bloomfield; Ella Donegan; Charles Baker

Testimonials

‘A team of people who are very experienced and show leadership – with a clear and obvious focus on client experience and best outcome.’  

They have an impressive breadth of expertise and experience.’

‘They handle the most complex transactions with calm authority, anticipating and flagging issues which need urgent attention, working closely with management to get the transaction done in the most efficient and speedy way.’

‘Ali Ramadan has a very commercial mindset, is truly valuable in assessing risks, pragmatic and available.’

Sophie McGrath is simply stellar when it comes to healthtech deals. She doesn’t just understand the law and the commercial dynamics but also how to steer a ship in a storm if needs be.’

Andrew Davis is phenomenal. Andrew is a genius at explaining even the most complex legal issues in terms understandable to lay people and offering options for resolutions.’

‘Elizabeth Rhodes stands out for her truly exceptional ability – she is technical, commercial, cool headed and strategic.’

Key clients

Matillion

Zapp

Vivid Money

Lightspeed Venture Partners

Jeito

Quanta Dialysis Technologies Limited

Tessian

Selina Finance

Better Dairy

Index Ventures

Octopus Investments

Hopin

Centessa

Evox Therapeutics

Work highlights

  • Advised Quanta Dialysis Technologies on its completion of a $245m oversubscribed Series D funding round, the largest private funding round for a dialysis device company in history.
  • Advised Matillion on its $150m Series E funding round, led by General Atlantic with participation from Battery Ventures, Sapphire Ventures, Scale Venture Partners and Lightspeed Venture Partners.
  • Advised Octopus Ventures on several investments including: Ibex Medial Analytics, Biofidelity, Taster, Contingent and Kleene.AI.

Investment fund formation and management > Private funds Tier 2

Goodwin has a broad practice, ranging from advising established fund managers on mega-cap fundraisings to acting for first-time managers on establishing smaller, more specialised funds. The team acts across a range of asset types, including private equity, infrastructure, real estate and credit and is also increasingly active in the secondaries space. It also stands out for the cross-jurisdictional nature of its work, with the London team frequently acting alongside the firm’s offices in the US as well as its growing Luxembourg team. Michael Halford leads the team and is praised as ‘one of the most intelligent and bright lawyers in the space’, with experience handling the structuring and fundraising of both bulge-bracket and mid-market funds. Ed Hall focuses on the private equity sector, including infrastructure PE, offering clients ‘intellect, experience and market knowledge’. Ravi Chopra, Ajay Pathak and Shawn D’Aguiar are other names to note in the team, winning instructions across fundraisings and secondary transactions. Hall and Chopra are ‘commercial, highly creative and totally unflappable’, while Pathak ‘strikes the right balance between technical excellence and finding the right fit for the client’. Counsel Benjamin Yeoh is another name to note with broad expertise across a range of asset classes.

Practice head(s):

Michael Halford

Other key lawyers:

Ed Hall; Ravi Chopra; Ajay Pathak; Shawn D’Aguiar; Benjamin Yeoh; Michael O’Brien Kelly

Testimonials

‘The Goodwin Procter team is my number one go-to firm with regards to fund structures and GP led secondaries. They are extremely knowledgeable about terms and trends in the market and have a collegial approach where they draw on the experience of tea members across the firm in a timely and fluid manner. They are extremely efficient and responsive, and always take matters beyond the task and think outside the box.’

‘Michael Halford is extremely professional yet very personable and true pleasure to work with. He is one of the most intelligent and bright lawyers in the space.’

‘Innovative, commercial, collaborative, technically very strong with a good awareness of market trends and terms.’

‘Ed Hall is our go to, trusted adviser. I have never gone into a negotiation with Ed on my side and felt out-gunned. Ed’s intellect, experience and market knowledge make him pre-eminent in his field. Alex Reda is a strong, up and coming junior associate.’

‘Our partners at Goodwin continue to demonstrate not just their deep market knowledge but a real creative flair for problem solving and bringing commercial solutions to knotty technical topics.’

‘Ravi Chopra & Ed Hall – they are bright, commercial, highly creative and totally unflappable.’

‘Pragmatism meets deep technical knowledge’

‘Ajay Pathak – pragmatic and strikes the right balance between technical excellence and finding the right fit for the client. Michael O’Brien Kelly stands out as a rising star on the Associate side.’

Key clients

Abingworth

Antin Infrastructure

Bregal Investments

Endless

Glennmont Partners

Intermediate Capital Group (ICG)

Investcorp

LGT

Macquarie

Patron Capital

Work highlights

  • Advised Cordet on a direct lending fund, Cordet Direct Lending Fund II, with a target fund size of €400 million.
  • Acting for Polaris in the formation of Polaris Private Equity V k/s, one of the leading mid-market Danish private equity funds.
  • Advised Abingworth on its proposed acquisition by global investment firm Carlyle

Industry focus > Hospitality and leisure Tier 3

Goodwin's team is well equipped to advise hospitality and leisure clients on the full gamut of issues that arise within the sector such as tax, privacy, employment, food and beverage and regulatory matters. The team advises clients on both the brand and operator side, as well as on both the debt and equity side of hotel and resort residential matters. The team is led by Matthew Pohlman. His focus lies within advising various industry stakeholders on the development, operation, management and financing of hotels, resorts and branded residential hospitality assets. Personal changes include the arrival of transactional real estate specialist Eric Lim from Baker McKenzie.

Practice head(s):

Matthew Pohlman

Testimonials

‘Consistent high quality service, year after year.’

‘Matthew Pohlman – extremely prepared, well versed and diligent. Able to communicate complex ideas and concepts very effectively.’

‘Great experience and tireless “can do” attitude.’

‘Matt Pohlman is highly professional, very well experienced, and always makes himself available.’

‘Their flexibility was a welcome change compared to other practices we have worked with.’

‘Matthew Pohlman: we were extremely happy to have him in our corner. Given his depth of experience it was not surprising how smooth the whole process was and his direct communication style with the counterparty’s legal team, helped save time for everyone.’

Key clients

Four Seasons Hotels and Resorts

Marriott International

Caesars Entertainment Corporation

Oaktree Capital Management

RoundShield Partners LLP

Angelo, Gordon & Co

Crossroads Real Estate

Firmdale Hotels

Cairn Hotel Group

Masterworks Development Corporation (a/k/a Club Quarters)

Away Resorts

Leeu Collection

Avington Financial

Hyatt Hotels

Work highlights

  • Advised Leeu Collection in connection with a suite of agreements with Auberge Resorts Collection related to the development, construction, management and branding of the Collegio alla Querce hotel together with agreements related to the financing of the development of the hotel.
  • Advised Away Resorts Limited, a holiday park owner and operator owned by CVC Capital Partners, in relation to their purchase of Golden Sands Holiday Park in north Wales for a purchase price of £17.9m.
  • Advised Away Resorts Limited on their purchase of St Ives Bay Holiday Park in Cornwall for a purchase price of £29.2m.

Industry focus > Life sciences and healthcare Tier 3

Leveraging the firm’s US strength, Goodwin’s practice handles a notable volume of cross-border mandates with particular expertise in corporate and financing transactions; the group recently advised Biocon Biologics on its acquisition of Viatris’ global biosimilars business for $3bn. Graham Defries, Malcolm Bates and David Mardle jointly lead the practice; Mardle and Defries are key names for corporate and finance work and Bates excels in IP, commercial and regulatory matters. The group was also bolstered with additional IP expertise in August 2022 with the recruitment of Morag Peberdy from Covington & Burling LLP.

Practice head(s):

Graham Defries; Malcolm Bates; David Mardle

Other key lawyers:

Andrew Harrow; Tim Worden; Morag Peberdy

Testimonials

‘Good understanding of the sector and what matters to biotech companies. Experience in licensing agreements on a global scale.’

‘The team at Goodwin not only guided an inexperienced management through the process, but had the strength and integrity to keep asking questions and not just make assumptions that that management team would know everything going on.’

‘Andrew Harrow was an exceptional part of the process we were involved in, with a simply outstanding knowledge of detail and fantastically personable approach. In addition, his level head helped myself and the team to navigate difficult passages of the deal flow. His team were also instrumental.’

‘For me Tim Worden provides super practical and pragmatic advice that is steeped in experience and he is valued in our business.’

‘Tim Worden is a fantastic contract lawyer and negotiator. His legal skill set is top and so is his negotiation skill set. Helped us tremendously through negotiations as our lead.’

‘We have been working with the Goodwin’s team for many years. They understand our business and the way we work, and are committed to ensuring successful outcomes to negotiations.’

‘Reputation in biotech area and knowledge of the sector. Building of an experienced team. Global capabilities including US resources.’

‘Andrew Harrow- sector knowledge including benchmarks and market norms, pragmatic, good communication- straightforward and open.’

Key clients

Kymab

CMR Surgical

Huma Therapeutics

Centessa Pharmaceuticals Limited

Biocon Biologics

Vaccitech

Syndesi Therapeutics

Dotmatics

In4Derm

SynAffix

Sparing Vision

Oxford Biomedica

Achilles

COMPASS Pathways

Quanta Dialysis Technologies Limited

Jeito

Work highlights

  • Advised Biocon Biologics on it’s acquisition of Viatris Inc’s global biosimilars business for $3.35bn.
  • Advised Achilles Therapeutics plc on its Initial Public Offering.
  • Advising Kymab on its agreement under which Sanofi will acquire Kymab for an upfront payment of approximately $1.1bn and up to $350m upon achievement of certain milestones.

Real estate > Commercial property: investment Tier 3

The London commercial property investment team at US firm Goodwin is known for handling complex real estate transactions and cross-border investment work. The team collaborates with the firm's finance, funds, tax, and regulatory practices to advise clients on the full life-cycle of a deal. James Spence and Martin Smith co-head the practice; Spence specialises in advising stakeholders on high value real estate investments and M&A transactions, while Smith's expertise is acting on asset and corporate SPV transactions. Chair of Goodwin's European offices David Evans specialises in fund restructuring and represents investment banks, hedge funds, and other investors. Justin Cornelius' expertise lies in the establishment and operation of real estate funds and joint ventures.  

Practice head(s):

James Spence; Martin Smith

Other key lawyers:

Key clients

Away Resorts

Cabot Properties

BentallGreenOak

Clarion Partners Europe

DWS

Kadans Science Partner

Kennedy Wilson

Medical Properties Trust

Partners Group

Workspace Group

Cerberus

Work highlights

  • Advising Clarion Partners Europe in relation to the sale of a corporate structure owning a portfolio of 31 institutional quality logistics properties located across Germany, the Netherlands, France, Spain, Slovakia and the Czech Republic, for a consideration which values the properties at over €880 million.
  • Advising MPT on its acquisition of a portfolio of select behavioural health facilities, and their concurrent leaseback, from the leading UK behavioural health provider The Priory Group.
  • Advising Cabot Properties on its agreement with Blackstone and two vehicles affiliated with Blackstone Real Estate to sell its institutional-quality logistics assets for $2.8 billion in two separate transactions.

Corporate and commercial > Corporate tax Tier 4

Goodwin‘s team is particularly active on funds and transactional tax matters. Laura Charkin leads the team, and is experienced in the full range of funds. Rob Young, who joined the department in 2019 from Taylor Wessing, advises on tax structurings and financings. David Irvine and Dulcie Daly both joined from Kirkland Ellis in 2021, and cumulatively bring over 35 years’ experience to the team. Katie Leah and Charlotte Haywood are also noted.

Practice head(s):

Laura Charkin

Other key lawyers:

David Irvine; Dulcie Daly; Robert Young; Katie Leah; Charlotte Haywood; Matthew Birchall

Testimonials

‘I find the quality, precision and accessibility of the advice provided to be superlative.’

‘Rob Young is brilliant! He has that great ability to provide advice on complex issues in a clear and accessible manner.’

‘The Goodwin tax practice partner was able to clearly articulate the matter at hand as well as make a recommendation that was aligned to UK requirements as well as our business needs. He was able to draw on practical and practiced experience to manage our expectations and demands.’

‘A knowledgeable team with depth in their practice.’

‘Excellent technical strength and breadth of team, availability of tax partner, and in-depth knowledge of complex matters. Bridge tax advice to implementation to corporate legal team very well.’

‘Dulcie is an excellent resource for deal advice and implementation. She is very user friendly and exceptionally hard working to deal with pressures of deal work.’

Key clients

Macquarie

Bregal Investments

Investcorp

Advent International

Glennmont Partners

Graphite Capital

M7 Real Estate

Mayfair Equity Partners

LGT Capital Partners

TowerBrook Capital Partners

Work highlights

  • Advised Ares Management Corporation on the structuring and fundraising of Ares European Property Enhancement Partners III SCSp.
  • Advised long-standing client GTT Communications, Inc., a global leader in the provisions of cloud networking services, on the sale of its global infrastructure business to I Squared Capital for US$2.15 billion.
  • Advised TA Associates on the merger of its portfolio company Soft Topco AS with 2020 Technologies Inc., a portfolio company of Genstar Capital.

Corporate and commercial > Private equity: transactions – high-value deals (£250m+) Tier 4

‘Responsive, commercially minded and  with good, broad experience’, Goodwin handled a steady stream of PE deals in 2021, acting for both the buy-side and sell-side. Alongside its work for an expanding client base of sponsors, the group is regularly engaged by management teams to handle sales to private equity and also acts for portfolio companies. Much of the rapidly growing team’s work is focused on the healthcare and technology sectors, and it also stands out for its ability to draw on its US links to handle transatlantic deals. Richard Lever heads the team and is ‘knowledgable, responsive and focused on getting the deal done’; other key names include James Grimwood, Gemma Roberts and Carl Bradshaw.

Practice head(s):

Richard Lever

Other key lawyers:

James Grimwood; Gemma Roberts; Carl Bradshaw; Erik Dahl; Christian Iwasko;

 

Testimonials

‘Responsive, commercially minded and with good broad experience’

‘We found Richard Lever very easy to deal with, knowledgable, responsive and focused on getting the deal done.’

 

Key clients

Accel-KKR

Antin Infrastructure Partners

Bregal Milestone

Graphite Capital

Inflexion Private Equity

Levine Leichtman Capital Partners

Mayfair Equity Partners

Queens Park Equity

TA Associates

TowerBrook Capital Partners

Work highlights

  • Advised longstanding client GTT Communications, Inc, a global leader in the provisions of cloud networking services, on the sale of its global infrastructure business to I Squared Capital for US$2.15 billion.
  • Advised longstanding client TA Associates on the merger of its portfolio company Compusoft, with 2020 Technologies Inc., a portfolio company of Genstar Capital. The transaction creates a merger of equals, making the new company a global provider of planning and manufacturing solutions for residential and commercial spaces.
  • Advised CSafe Global, a portfolio company of Frazier Healthcare Partners and Thomas H. Lee Partners, on the completion of its acquisition of Softbox Systems, provider of temperature control packaging to the biotech and pharmaceutical industries. Notably, Softbox supplies Pfizer with the ultra-low temperature controlled parcel shipper required in the distribution of its Covid-19 vaccines.

Real estate > Property finance Tier 4

Goodwin ‘demonstrates strength in depth‘ and has particular experience in debt-related transactions, mezzanine financing and CMBS loans both. Practice head Paul Lyons advises borrowers and lenders, and the ‘strong hire‘ Richard Semple and Geoff O’Dea are also notable team members.

Practice head(s):

Other key lawyers:

Richard Semple; Toby Young; Emily Lockhart; Geoff O’Dea

Testimonials

‘The team demonstrates strength in depth.’

‘Richard Semple is a strong hire and has significantly expanded the Goodwin Real Estate Finance offering.’

‘Richard Semple is building a strong team and delivers an excellent level of service, attention to detail and commercial awareness.’

‘Counsel Toby Young is recommended.’

‘Paul Lyons leads exceptionally well.’

‘Associate Emily Lockhart is very responsive and insightful.’

Finance > Acquisition finance Tier 5

Under the expert guidance of Simon Fulbrook, Goodwin's 'very pragmatic and commercial' three-partner leveraged finance team continues to gain momentum in the market on behalf of its growing sponsor client base. Unsurprisingly, given the firm's overarching sector expertise and venture capital credentials, a sizeable volume of financing work relates to tech-related M&A. Geoff O'Dea 'has excellent technical knowledge', particularly on behalf of funds clients in the distressed space.

Practice head(s):

Simon Fulbrook

Other key lawyers:

Hugh O’Sullivan; Geoff O’Dea; Richard Hughes; Thomas Plowman

Testimonials

The team is very pragmatic and commercial; it reaches the right outcome with very little fuss.’

Driven, motivated, always keen to get to the right solution. The team provides clear and cogent communication.’

Geoff O’Dea has excellent technical knowledge.’

Key clients

ECI Partners

HoldCo SAS

LDC

Mayfair Equity Partners

Partners Group

Queens Park Equity

Stellex Capital

TA Associates

Tiancheng International Investment

Wavecrest Partners

G Square Private Equity

H.I.G. Capital

Inflexion

Work highlights

  • Advised HoldCo SAS, a holding company controlled by Xavier Niel, in relation to the financing of the simplified public tender offer for iliad SA shares launched by HoldCo II.  
  • Advised Mayfair Equity Partners on its acquisition of the entire issued share capital of Tangle Teezer Limited, a global hairbrush brand.
  • Advised Tiancheng International Investment on several high-profile transactions, including on the disposal of its majority stake in Bio Products Laboratory, a specialist in the development of rare disease products using fractionated blood plasma, to Permira.

Risk advisory > Data protection, privacy and cybersecurity Tier 5

Goodwin is particularly known for its strong expertise in emerging technologies and the life sciences sector, and is rated for its 'solid advice and guidance'. Co-practice head Gretchen Scott draws on more than 20 years of experience in advising tech and data driven businesses on global compliance projects, investigations and incident response. Co-practice head Lore Leitner is highly regarded as 'truly excellent, super pragmatic, commercial and thorough', and is a key contact for GDPR work and the privacy and data protection matters related to corporate transactions. Also noted is counsel Curtis McCluskey.

Practice head(s):

Gretchen Scott; Lore Leitner

Other key lawyers:

Testimonials

‘The Goodwin Team is supremely knowledgeable in the field but also demonstrates realism and pragmatism when understanding the nature of any data protection and privacy challenges. The team uses its expertise and experience to provide solid advice and guidance. They are always on hand, quick to respond and are also lovely to interact with.’

‘Gretchen Scott and Curtis McCluskey are personable, friendly and helpful. I value their opinion and also really enjoy interacting with them as there is mutual respect and an openness to learn and adapt.’

‘Strong bench and very well connected.’

‘Lore Leitner is truly excellent, super pragmatic, commercial and thorough.’

‘I have had the pleasure of working with Curtis McCluskey over the past 18 months as my primary GDPR and data privacy advisor. I have come to rely upon his counsel and partnership for all data privacy matters.’

‘Curtis McCluskey is very client oriented and provides clear input and advice.’

‘Great specialists. Very user friendly and prompt to reply. A reliable external adviser in this field.’

‘Gretchen Scott is excellent.’

Key clients

Allurion Technologies

AM Pharma

Andreessen Horowitz

Bank Delen

Bregal Sagemount

BrightHire

Celsius Therapeutics

Collibra

Couchsurfing International

Dotmatics

Epic Staffing

FIA Technology

GlobalGiving

Hivemapper

HungryPanda

LendingTree

Meta

National Public Radio

Peanut App

Permutive

Pfizer

Repligen

RocketReach

TA Associates

Teva

Theradex Oncology

TowerBrook Capital

Triton

Webster Equity Partners

Whoop

Work highlights

  • Advised Andreessen Horowitz on a number of high-stakes investments in emerging companies with significant global privacy and data protection considerations.
  • Acted for Meta on the development of the first EU-wide code of conduct under the GDPR.
  • Assisted Deliveroo and its global privacy team with all aspects of its privacy and data protection compliance matters across a number of jurisdictions.

Finance > Corporate restructuring & insolvency Tier 6

Drawing on a 'combination of deep legal and sector knowledge, while remaining commercial and practical', Goodwin continues to gain traction in the London restructuring market, both on standalone domestic mandates, as well  cross-border matters - where it often works alongside practitioners in the firm's more well-established New York office. Simon Thomas 'displays a great mix of technical skill and a commercial approach' and has strong ties with the IP community, in particular. The team has also effectively exploited the firm's broader private equity/funds expertise, and has begun to pick up a considerable amount of work on their stressed/distressed investments. This side of the practice was also recently enhanced by the arrival of counsel Tony Horspool  from Brown Rudnick LLP. The 'creative, responsive and focused' Geoff O'Dea co-heads the team alongside Thomas and is a double threat by dint not only of his core restructuring prowess (which includes great knowledge on schemes and restructuring plans) but also on leveraged finance transactions.

Practice head(s):

Simon Thomas; Geoff O’Dea

Other key lawyers:

Tony Horspool; Oonagh Steel; Thomas Plowman; Emily Lockhart

Testimonials

‘Excellent combination of deep legal and sector knowledge while remaining commercial and practical.’

It is a well-connected team with strong technical skills.’

‘Simon Thomas displays a great mix of technical skill and a commercial approach.’

Geoff O’Dea is one of the leading restructuring lawyers in the market and a renowned expert on schemes and restructuring plans.’

‘Geoff O’Dea is one of the very rare lawyers in the market who is excellent at both leveraged finance and restructuring. Very strong commercial capabilities and extremely creative, responsive and focused.’

Oonagh Steel and Emily Lockhart demonstrate experience and knowledge beyond their years of experience, and take carriage of matters, seeing them through to conclusion or resolution.’

Key clients

Teneo

Partners Group

PwC

Medical Properties Trust (MPT)

Kroll

Interpath Advisory

EY

Madison Pacific

Alvarez & Marsal

FRP

Work highlights

  • Instructed on US aspects of the  Arena Television administration by Kroll.
  • Advising Madison Pacific on: Amendment and restatement of the trade finance facility; Enforcement documentation in connection with security enforcement and sale of the Noble Group to a Bidco; Interim intercreditor agreement and interim security documents; and Final restructuring intercreditor agreement, new term debt facility agreement and security documents.  
  • Acting for the administrators of Arcadia (also known as Top Shop, Sir Philip Green’s fashion empire) in relation to US tax advice.

Corporate and commercial > EU and competition

Dispute resolution > Banking litigation: investment and retail

Dispute resolution > Commercial litigation: premium

Goodwin launched its commercial litigation practice with the arrival of Oliver Glynn-Jones from Bryan Cave Leighton Paisner LLP in April 2020, and team growth continued apace with the hire of Hannah Field from White & Case LLP in April 2021.

TMT (technology, media and telecoms) > IT and telecoms

Goodwin‘s technology practice is adept at advising clients on licensing and technology transfer transactions. Lore Leitner joined the team from Wilson Sonsini Goodrich & Rosati in December 2021 to lead the practice alongside Gretchen Scott.

East Anglia > Corporate and commercial > Corporate and commercial: Cambridge

Goodwin's Cambridge office plays a key role in the firm's globally recognised technology and life sciences practice, which frequently assists private and public companies, venture capital funds and investment firms with early-stage financings, capital markets issuance, M&A, strategic collaborations and licensing transactions. David Mardle, Malcolm Bates and Tim Worden are the lead partners. Mardle acted for fast-growing start-up Hopin in its $450m funding round and in the acquisitions of Streamable, Jamm, Boomset and Attendify. Worden assisted spin-out life sciences company In4Derm Limited with a licence agreement for a new oncology treatment. Newly promoted partner Elizabeth Rhodes and associate Adam Thatcher, who both focus on VC and M&A transactions, are also recommended.

Practice head(s):

Malcolm Bates; David Mardle; Tim Worden

Other key lawyers:

Key clients

Moderna

Evox Therapeutics

Kymab

Oxford Biomedica

Calliditas Therapeutics

InBrain

Avacta

SparingVision

CIC

Tropic Biosciences

Index Ventures

MiNA Therapeutics

Avacta Group

Work highlights

  • Advised Teva Pharmaceutical Industries Ltd. on a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433.
  • Advised Calliditas Therapeutics AB on a strategic licence agreement with STADA Arzneimittel AG to register and commercialize a novel specialty drug candidate for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy (IgAN) in the European Economic Area member states, Switzerland and the UK.
  • Advising Kymab on its agreement under which Sanofi will acquire Kymab for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones.

East Anglia > TMT (technology, media and telecoms) > Intellectual property

Goodwin‘s Cambridge office has ‘unique experience in life sciences and excellent knowledge of and extensive experience in IP contracting enables the team to provide relevant advice in relation to complex IP arrangements‘. The firm is frequently involved in helping companies to develop emerging life sciences and technologies, including Covid-19 vaccines, and it counts Oxford Biomedica, Teva and Avacta among its high-profile clients. Malcolm Bates (who has ‘a commercial and pragmatic approach to contract negotiations‘) and Tim Worden (who ‘cuts through the underbrush and pushes transactions forward‘) work from both Cambridge and London and lead the technology and life sciences practice. Counsel Talitha Shkopiak and associates Georgia Powell and Samantha Deacon also play pivotal roles in the practice. Worden and Powell assisted University of Dundee spinout In4Derm to licence a new treatment for immunology and oncology conditions.

Practice head(s):

Malcolm Bates; Tim Worden

Testimonials

‘The firm has knowledge of IP practices and IP licensing in biotech, understanding of what is important to biotech companies.’

‘Partners and associates have broad experience on global license agreements and have suggested useful solutions during the negotiation and contract drafting phase.’

‘Malcolm Bates and Tim Worden are excellent, pro-active, business-minded professionals who cut through the underbrush and push transactions forward.’

‘Unique experience in life sciences. Excellent knowledge and extensive experience of IP contracting enables the team to provide relevant advice in relation to complex IP arrangements.’

‘Malcolm Bates is hugely experienced and understands our business and requirements really well. He has a commercial and pragmatic approach to contract negotiations.’

‘Talitha Shkopiak is very tenacious and able to redraft the incomprehensible so that it makes sense!’

‘Georgia Powell has provided reliable, solid advice on a number of agreements.’

Key clients

Novasep

Oxford Biomedica

Calliditas Therapeutics

CMR Surgical

In4Derm

Orexia Therapeutics

Teva

InBrain

Avacta

SparingVision

SynAffix

Ellipses Pharma

Work highlights

  • Advised Teva Pharmaceutical Industries Ltd. on a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433.
  • Advised Calliditas Therapeutics AB on a strategic licence agreement with STADA Arzneimittel AG to register and commercialize a novel specialty drug candidate for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy (IgAN) in the European Economic Area member states, Switzerland and the UK.
  • Advising Kymab on its agreement under which Sanofi will acquire Kymab for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones.

East Anglia > TMT (technology, media and telecoms) > Biotechnology

Goodwin has 'an understanding of the biotech landscape, the pressures on biotech companies and the experience in biotech licensing deals globally'. Clients remark that one of its key strengths is its 'experienced associates who work autonomously, closely in communication with partners', resulting in a practice that is 'very responsive and able to provide creative proposals to address potential problems'. Among its clients are pharmaceutical company Teva and gene and cell therapy company Oxford Biomedica. The practice is led by life sciences and technology M&A and finance partner David Mardle, commercial IP specialist Malcolm Bates and licensing and contracts expert Tim Worden, who all work in both the Cambridge and London offices. Newly promoted counsel Talitha Shkopiak specializes in commercial agreements forthe creation and commercialisation of IP rights, notably for biotechnology companies.

Practice head(s):

Malcolm Bates; David Mardle; Tim Worden

Other key lawyers:

Testimonials

‘Understanding of the biotech landscape, the pressures on biotech companies and experience on biotech licensing deals globally.’

‘Experienced associates that work autonomously, closely in communication with partners.’

‘Very responsive and able to provide creative proposals to address potential problems.’

‘Thorough and significant sector knowledge and experience.’

‘I had the opportunity to interact with two different lawyers at Goodwin and I have to say that the negotiation certainly improved thanks to the feedback received and the team style. I was provided with clear recommendations and/or clear consequences from accepting or not the recommendations in a way that the negotiation with the partner became much more intuitive and clear.’

‘They have gravitas and courage to actually help guiding the negotiation when needed.’

‘Extremely positive experience working with the Goodwin team on a pharma licensing transaction. Felt they really cared about the transaction and made themselves available day and night to meet very tight deal deadlines.’

‘Tim Worden is extremely knowledgeable and experienced on all aspects licensing transactions. A very calm but engaging personality. He is very good at highlighting and then resolving different challenges arising in a negotiation. I always have the impression nothing gets past Tim which gives me comfort we have the right lawyer representing us.’

Key clients

Novasep

Oxford Biomedica

Calliditas Therapeutics

CMR Surgical

In4Derm

Orexia Therapeutics

Teva

InBrain

Avacta

SparingVision

SynAffix

Ellipses Pharma

Work highlights

  • Advised Teva Pharmaceutical Industries Ltd on a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433.
  • Advised Calliditas Therapeutics AB on a strategic licence agreement with STADA Arzneimittel AG to register and commercialize a novel specialty drug candidate for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy (IgAN) in the European Economic Area member states, Switzerland and the UK.
  • Advising Kymab on its agreement under which Sanofi will acquire Kymab for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones.
X

With the breakneck pace of technology disrupting industries around the world, our London-based team of 100+ lawyers is embracing change to help clients make a lasting and meaningful impact. As part of what is widely recognised as one of the fastest growing international firms in London, our lawyers are deeply experienced in the life sciences, technology, real estate and private equity sectors and are supported by significant on-the-ground capabilities in debt financing, intellectual property, privacy and cybersecurity, regulatory, restructuring, tax and litigation and dispute resolution.

In 2019 we also launched our Cambridge office in the heart of the high-technology Silicon Fen, and home to one of the world’s largest and most innovative life sciences clusters, as well as some of the most disruptive technology and life sciences companies. The firm’s on-the-ground presence in Cambridge further expands our lawyers’ ability to support clients in these sectors through our unique capital-meets-innovation platform in Europe, and solidifies Goodwin’s position as the leading firm in the UK and European life sciences and technology markets.

Real estate: Our real estate lawyers provide a genuinely integrated offering from structuring funds, products and vehicles, to the acquisition, financing, development, restructuring and disposal of real estate assets through direct and indirect investments, as well as complex international hospitality + leisure transactions.

Private equity: Our private equity lawyers counsel on all areas of private equity and mergers and acquisitions, with a special emphasis on middle market private equity and growth investments, alongside our renowned private funds team, which provides counsel at every stage of the fund life cycle.

Technology and life sciences: Our technology and life sciences lawyers help high growth businesses, public companies, investors and investment banks capitalise on opportunities and minimise risks in rapidly evolving markets. We offer clients industry-leading technology, life sciences and healthcare practices recognized for serving clients along the corporate life cycle globally.

Private investment funds: Goodwin’s London funds team uniquely covers the full range of private investment funds including private equity funds, venture capital funds, real estate funds, infrastructure funds, debt funds, impact and responsible investing funds, emerging market funds, hedge funds and listed funds as well as various large-scale GP led structures.

Tax: Our tax team have extensive experience of the tax issues affecting the private equity, infrastructure and real estate industries. This sector focus means that our tax team can save you time and money by delivering pragmatic and commercially relevant advice grounded not only in technical expertise and experience but also in a deep understanding of the issues affecting the markets in which you operate. By working as integral parts of our transaction and fund formation teams to ensure that tax advice is robustly implemented, our tax lawyers minimise the risk of challenge by a tax authority and the cost and possible reputational damage that can result from such a challenge.

Restructuring: Our London financial restructuring lawyers represent every type of major stakeholder in distressed situations. The restructuring and insolvency advice provided by our team complements the other services provided by Goodwin during the full life cycle of each company and investment to achieve the optimum outcome for stakeholders

Litigation: Our London team has over 20 years’ experience advising investment and retail banks, funds, issuers, bondholders and other financial counter-parties in the resolution of complex corporate disputes, often with a cross-border element. The team has litigated across many different fields of finance, with a particular focus on investment banking, structured finance and funds litigation.

Regulatory: Our regulatory team is uniquely positioned to address the cutting-edge issues that can maximize business opportunities as well as better manage and mitigate risk. Our team of specialists represent investment managers on the formation, offering and operation of investment products including real estate, private equity, infrastructure + energy, private debt, hedge, venture funds, fund of funds, and joint ventures.  We have experience advising clients on matters under the EU AIFMD, EU MIFID, UK Financial Services and Markets Act 2000 and the UK Financial Conduct Authority’s Rules and are currently helping clients navigate their way through the post-Brexit landscape. We also advise clients on issues relating to the US Investment Advisers Act of 1940 and the US Investment Company Act of 1940 including registration and compliance matters.

DepartmentNameEmailTelephone
London office co-chairs Samantha Lake Coghlanslakecoghlan@goodwinlaw.com+44 (0)20 7447 4203
London office co-chairs Paul Lyonsplyons@goodwinlaw.com+44 (0)20 7447 4233